MedTrace Logo

Clinical Study Evaluating the Efficacy and Safety of Colchicine in Adult Patients With Sepsis

NCT07074990 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2025-07-23

No results posted yet for this study

Summary

Inflammatory markers are found to be an important contributor in sepsis. We evaluate the effect of colchicine on inflammatory processes and its possible protective effect against oxidative stress and organ dysfunction in adult patients suffering from sepsis.

Conditions

  • Sepsis at Intensive Care Unit

Interventions

DRUG

conventional sepsis therapy alone

fluid resuscitation a minimum of 30 mL/kg of intravenous (IV) crystalloid fluid administered during the initial 3 hours of resuscitation, along with empiric antibiotic therapy aimed at the suspected pathogens and infection sites, ideally starting within the first hour.

DRUG

colchicine 500 mcg oral twice daily plus conventional sepsis therapy.

colchicine 500 mcg oral twice daily plus conventional sepsis therapy for 5 days.

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-01
Primary Completion
2024-08-30
Completion
2024-08-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07074990 on ClinicalTrials.gov